Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28306346 | 0.74 | CA2 (0.31) | — | |
| SCHEMBL28543862 | 0.73 | FDPS (0.35) | FDPS | |
| SCHEMBL28831024 | 0.71 | GABBR1 (0.32) | — | |
| SCHEMBL16446620 | 0.68 | — | — | |
| SCHEMBL826374 | 0.67 | FDPS (0.35) | FDPS | |
| SCHEMBL12432928 | 0.64 | HPGD (0.33) | FDPS | |
| SCHEMBL8763211 | 0.63 | — | — | |
| SCHEMBL28768620 | 0.62 | FDPS (0.33) | FDPS | |
| SCHEMBL2243001 | 0.61 | FAAH (0.32) | — | |
| SCHEMBL10345877 | 0.61 | FDPS (0.42) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF (US) | 2019-01-31 | — | — | US | disclosed |
| US-10087204-B2 | Methods and compositions for substituted alpha-aminophosphonate analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267707-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | FDPS 51/4885 |
| US-20190031695-A1 | Methods and Compositions for Substituted Alpha-Aminophosphonate Analogues | NPEPPS, AGPS, PHOSPHO1 | FDPS 51/4885 |
| US-10087204-B2 | Methods and compositions for substituted alpha-aminophosphonate analogues | NPEPPS, AGPS, PHOSPHO1 | FDPS 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.